Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marieke Krol

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Social Science & Medicine (1982)|October 1, 2015
Unpaid work in health economic evaluationsMarieke Krol, Werner Brouwer
Expert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
Economic evaluations in European reimbursement submission guidelines: current status and comparisonsAndrea Bracco, Marieke Krol
Pharmacoeconomics|February 8, 2014
How to estimate productivity costs in economic evaluationsMarieke Krol, Werner Brouwer
Pharmacoeconomics|April 27, 2013
Productivity costs in economic evaluations: past, present, futureMarieke Krol, Werner Brouwer, Frans Rutten
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 14, 2013
Predicting productivity based on EQ-5D: an explorative studyMarieke Krol, Elly Stolk, Werner Brouwer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2008
Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercisesMarieke Krol, Pedram Sendi, Werner Brouwer
Pharmacoeconomics|April 12, 2006
Productivity costs in health-state valuations : does explicit instruction matter?Marieke Krol, Werner Brouwer, Pedram Sendi
Patient Preference and Adherence|July 27, 2017
Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart<sup>®</sup> injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosisMarieke Krol, Gert de Voer, Ulrike Osowski
Pharmacoeconomics|October 16, 2014
Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studiesMarieke Krol, Jocé Papenburg, Job van Exel
Journal of Comparative Effectiveness Research|May 19, 2018
Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database studyServaas Buijs, Marieke Krol, Gert de Voer
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Social Science & Medicine (1982)|October 1, 2015
Unpaid work in health economic evaluationsMarieke Krol, Werner Brouwer
Expert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
Economic evaluations in European reimbursement submission guidelines: current status and comparisonsAndrea Bracco, Marieke Krol
Pharmacoeconomics|February 8, 2014
How to estimate productivity costs in economic evaluationsMarieke Krol, Werner Brouwer
Pharmacoeconomics|April 27, 2013
Productivity costs in economic evaluations: past, present, futureMarieke Krol, Werner Brouwer, Frans Rutten
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 14, 2013
Predicting productivity based on EQ-5D: an explorative studyMarieke Krol, Elly Stolk, Werner Brouwer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2008
Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercisesMarieke Krol, Pedram Sendi, Werner Brouwer
Pharmacoeconomics|April 12, 2006
Productivity costs in health-state valuations : does explicit instruction matter?Marieke Krol, Werner Brouwer, Pedram Sendi
Patient Preference and Adherence|July 27, 2017
Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart<sup>®</sup> injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosisMarieke Krol, Gert de Voer, Ulrike Osowski
Pharmacoeconomics|October 16, 2014
Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studiesMarieke Krol, Jocé Papenburg, Job van Exel
Journal of Comparative Effectiveness Research|May 19, 2018
Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database studyServaas Buijs, Marieke Krol, Gert de Voer
Pageof 4